Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01210495 · ClinicalTrials.gov registry record · Phase 2
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
A Phase 2 study of Hepatocellular Carcinoma, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
- 20
- Study locations
NCT01210495 is a Phase 2 study of Hepatocellular Carcinoma that has completed, run by Pfizer. The registered enrollment target is 224 participants, below the 256-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT01210495, a Phase 2 study of Hepatocellular Carcinoma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Axitinib (AG-013736)
- OTHER Best Supportive Care
Study Locations (20)
California
- Alta Bates Summit Comprehensive Cancer Center - Berkeley
- UCSD Medical Center- La Jolla - La Jolla
- Moores UCSD Cancer Center - La Jolla
- University of California Irvine Medical Center - Orange
- UCSD Medical Center- Hillcrest - San Diego
Florida
- Florida Hospital Transplant Center, Liver Unit - Orlando
- Moffitt Cancer Center & Research Institute - Tampa
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
- Comprehensive Cancer Centers of Nevada - Las Vegas
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- Penn Presbyterian Medical Center - Philadelphia
Other
- Universitair Ziekenhuis Gent - Ghent
- CHC Clinique Saint-Joseph - Liège
Jiangsu
- Nanjing Bayi Hospital - Nanjing
- Jiang Su Cancer Hospital - Nanjing
Michigan
- University of Michigan - Ann Arbor
Nebraska
- Nebraska Methodist Hospital - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2010-12-06 |
| Est. Completion | 2016-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01210495
The ClinicalTrials.gov registry entry for NCT01210495 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 256-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (12% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01210495 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Nevada.
Frequently Asked Questions
What is clinical trial NCT01210495 about?
NCT01210495 is a clinical study titled "Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma". The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.
What is the current status of trial NCT01210495?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2010-12-06. Estimated completion is 2016-12-20.
What conditions does trial NCT01210495 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT01210495?
The interventions under investigation include: Placebo (DRUG), Axitinib (AG-013736) (DRUG), Best Supportive Care (OTHER).
Who is sponsoring clinical trial NCT01210495?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01210495 being conducted?
This trial has 20 study locations across California, Florida, Michigan, Nebraska, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.